Sanofi "A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patinets with polymyalgia rheumatic"
This study will last up to 62 weeks and made up of 3 periods:
- Screening Period: will last up to 4 weeks.
- Study Treatment period: will last 52 weeks.
- Follow-up period: Will last 6 weeksfrom the end of the study trematment period.
Diagnosis of PMP accrding to the European Leauge against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria as follows ( must satisfy all criteria ) :
a) Age ≥50 years at time of diagnosis
b) Bilateral shoulder pain
c) Elevated acute phase reactants ( CRP >10 mg/L and/or ESR >30 mm/hr).